Abstract
The development of vaccines against rare emerging infectious diseases is hampered by many disincentives. In the face of growing in-house expenditures associated with research and development projects in a complex legal and regulatory environment, most pharmaceutical companies prioritize their projects and streamline their product portfolio. Nevertheless, for humanitarian reasons, there is a need to develop niche vaccines for rare diseases not preventable or curable by other means. The U.S. Orphan Drug Act of 1983 and a similar proposal from the European Commission (currently under legislative approval) provide financial and practical incentives for the research and development of drugs to treat rare diseases. In addition, updated epidemiologic information from experts in the field of emerging diseases; increased disease awareness among health professionals, patients, and the general public; a list of priority vaccines; emergence of a dedicated organization with strong leadership; and the long-term pharmacoeconomic viability of orphan products will be key factors in overcoming the complexity of orphan status and the limited need for vaccine.
Full Text
The Full Text of this article is available as a PDF (78.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beutels P. Economic evaluations applied to HB vaccination: general observations. Vaccine. 1998 Nov;16 (Suppl):S84–S92. doi: 10.1016/s0264-410x(98)00305-3. [DOI] [PubMed] [Google Scholar]
- Hausdorff W. P. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine. 1996 Sep;14(13):1179–1186. doi: 10.1016/s0264-410x(96)00024-2. [DOI] [PubMed] [Google Scholar]
- Hillcoat B. L. Rare diseases and "orphan" drugs. Med J Aust. 1998 Jul 20;169(2):69–70. doi: 10.5694/j.1326-5377.1998.tb140184.x. [DOI] [PubMed] [Google Scholar]
- Mahoney R. T., Maynard J. E. The introduction of new vaccines into developing countries. Vaccine. 1999 Feb 26;17(7-8):646–652. doi: 10.1016/s0264-410x(98)00246-1. [DOI] [PubMed] [Google Scholar]
- Maiztegui J. I., McKee K. T., Jr, Barrera Oro J. G., Harrison L. H., Gibbs P. H., Feuillade M. R., Enria D. A., Briggiler A. M., Levis S. C., Ambrosio A. M. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis. 1998 Feb;177(2):277–283. doi: 10.1086/514211. [DOI] [PubMed] [Google Scholar]
- Scharf S. F. Orphan drugs: the question of products liability. Am J Law Med. 1985 Winter;10(4):491–513. [PubMed] [Google Scholar]
- Shepard D. S., Walsh J. A., Kleinau E., Stansfield S., Bhalotra S. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine. 1995;13(8):707–714. doi: 10.1016/0264-410x(94)00063-s. [DOI] [PubMed] [Google Scholar]
- Thamer M., Brennan N., Semansky R. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act. J Health Polit Policy Law. 1998 Apr;23(2):265–290. doi: 10.1215/03616878-23-2-265. [DOI] [PubMed] [Google Scholar]
- Trannoy E. Will ethical and liability issues and public acceptance allow maternal immunization? Vaccine. 1998 Aug-Sep;16(14-15):1482–1485. doi: 10.1016/s0264-410x(98)80005-4. [DOI] [PubMed] [Google Scholar]